ANRO
Alto Neuroscience, Inc.
$34.28
+0.09%
2026-08-21
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Key Fundamentals
Forward P/E
-9.57
EPS (TTM)
$-2.32
ROE
-49.2%
Profit Margin
0.0%
Debt/Equity
10.62
Price/Book
5.14
Beta
1.09
Market Cap
$1.26B
Avg Volume (10D)
476K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$35.41
60D Low
$17.90
Avg Volume
517K
Latest Close
$34.28
Get breakout alerts for ANRO
Sign up for Breakout Scanner to receive daily notifications when ANRO triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Alto Neuroscience, Inc. (ANRO) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors ANRO daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ANRO operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.